NEW YORK (GenomeWeb News) – Consumer genomics firm GeneLink reported that its first-quarter revenues dropped 45 percent year over year following the sale of its GeneWize Life Sciences subsidiary.

For the three months ended March 31, the Orlando, Fla.-based company posted $771,664 in revenues, down from $1.4 million a year ago, it said in its Form 10-Q filed with the US Securities and Exchange Commission on Monday.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.